nrick Analytics
nrick.com
stin, TX

Project 145064
Lab # 201227
Date Rec'd 2/11/2026
Report Issued 3/2/2026

Certificate of Analysis



Compound Tirzepatide
Label Claim 30 mg
Batch/Lot 953vuxc

lyte	Result	Units	LOQ	% of Label	Method	Date	CAS
tide Analysis							
omatographic purity	99.87	%	0.5		HPLC-UV/MS	2/14/2026	
epatide	30.4	mg	0.5	101.4	HPLC-UV-MS	2/14/2026	2023788-19-2
epatide	ID Confirmed				HPLC-UV-MS	2/14/2026	
crobiology							
otoxins	<0.5	EU	0.5		USP 86	2/28/2026	

The data presented are from the analysis of the sample shown and meet Krause Analytical internal quality assurance criteria unless otherwise flagged.
Methods shown reference current Krause Analytical SOPs
ND - Not detected LOQ - limit of quantification
All values reported on a per vial basis unless otherwise noted

Respectfully submitted,

bMark C.

Krause
Laboratory Director

8127 Mesa Drive Suite B-206 Austin, TX 78759

worldwidepeptidedistribution@gmail.com

Methods Summary

Purity/Potency/Identification **USP/NF 621**

- 2 mL of purified water is added to the lyophilized powder in the vial, and the contents mixed to dissolve the lyophilized powder.
- An aliquot is taken from the vial and diluted to contain approximately 500 mg/L of the peptide.
- The diluted sample is analyzed by HPLC-UV-MS.
- The mass spectrum obtained is compared to an authentic standard of the peptide for identification.
- The total area of all of the peaks in the chromatogram is calculated, and the area of the peak of the peptide is divided by the total area to obtain the chromatographic purity value, reported in percent.
- The area of the peptide is compared to the area of the peptide peak in the known standard to obtain a concentration in the solution. This concentration is used to calculate the total mass of peptide in the vial, which is compared to the stated mass (label claim) and reported as both total mass in the vial and as a percent of the label claim.

Endotoxins **USP/NF 85**

- 2 mL of purified water is added to the lyophilized powder in the vial, and the contents mixed to dissolve the lyophilized powder.
- An aliquot is taken from the vial and diluted in endotoxin-free water.
- The diluted sample is analyzed for endotoxins using the LAL method.

Metals **USP/NF 233**

- 2 mL of purified water is added to the lyophilized powder in the vial, and the contents mixed to dissolve the lyophilized powder.
- An aliquot is taken from the vial and diluted in deionized water.
- The diluted aliquot is analyzed against known standards by ICP-MS

PRE-PUBLICATION RESULTS PREVIEW

Visible to anyone with the URL, but not listed on Tirzepatide from Sihai Technology, not yet included in rating calculation. **Will be published soon.**

Sample Details

Sihai Technology

Tirzepatide 30mg

This is an unpublished test of Tirzepatide from Sihai Technology. No other such tests have yet been published to the Finnrick web site.

DATE RECEIVED	PHYSICAL DETAILS
11 Feb 2026	No Label / Silver Crimp / Black Cap

Test Details

Commercial Lab Test

TESTED ON **2 Mar 2026**

TESTING LAB **Krause Analytical**

Download lab test certificate

View original COA from Krause Analytical.

Test My Tirzepatide Sample

Mail in a sample for **free testing** (US only, terms apply)

TEST SCORE

7.9 / 10

3.9 / 4 Purity

4.0 / 4 Quantity

0.0 / 2 Identifier

Endotoxins: Below LOQ

Share These Results

Calculating The Test Score

Test score calculated by Finnrick from **purity** (how much of the vial content is the expected compound, with the closest value to 100% the better, and values below 98% considered unaccceptable), **quantity** (how close the actual amount in the vial is to the advertised value, more than +/-20% is not acceptable), and **identifier** (track the batch this vial was a part of).

Purity

99.87%

Purity Component

3.9 / 4

Tested purity between 99.5 and 99.9%, resulting in a score of 3.9 out of 4 maximum points.

Quantity Information

Quantity Divergence

Quantity Component